The commitment is part of Roche’s recently announced $50 billion investment in the U.S., but a company spokesperson said that ...

Novartis’ head of drug development Vas Narasimhan talks about the company’s stake in CAR-T immunotherapy. These cell therapies are set to transform treatment of blood cancers – but questions ...

With President Donald Trump expected to deliver a drug pricing order on Monday that Big Pharma and patient groups alike have ...

Vas Narasimhan is global head of drug development and chief medical officer at Novartis, and spoke to pharmaphorum at the company’s recent Q4 results conference. He says numerous pilot studies ...

The TIME100 Health list, assembled by the American news magazine TIME, highlights global leaders, advocates, and innovators ...

Coordinating Minister of Health and Director of Nutrition have been named among TIME magazine’s 100 Most Influential People in Global Health.

Novartis chief executive Vas Narasimhan, already eyeing a possible divestment of generics business Sandoz, has now turned his attention to the rest of the company. The Swiss group will see major ...

I spoke to Bradner at the company’s headquarters in Basel, Switzerland, on the day it unveiled its full-year results, and just a few days ahead of Vas Narasimhan taking over as chief executive.

CEO of Novartis Vas Narasimhan, vice president of health at Apple Sumbul Desai, Global Health Council president Elisha Dunn-Georgiou, US FDA commissioner Marty Makary and many more.

CEO of Novartis Vas Narasimhan; Apple's vice president of health Sumbul Desai; Global Health Council president Elisha Dunn-Georgiou; and US FDA commissioner Marty Makary, among others.

Novartis’ new CEO Vas Narasimhan has said he wants to cut R&D costs by using digital tech, and has followed through by scaling up a virtual clinical trials collaboration with startup firm ...